The mood at this year’s J.P. Morgan Healthcare Conference was one of exuberance, as industry professionals gathered to share and hear major deals news from Eli Lilly & Co, SAGE, and others, and to herald exciting scientific news, especially in the area of gene therapy. What was not being discussed: US drug pricing and political issues. Scrip was there, reporting on the major announcements and developments to come out of the meeting in San Francisco, and also noting the significance of what was not being discussed.